当前位置:首页 - 行情中心 - 微芯生物(688321) - 财务分析 - 现金流量表

微芯生物

(688321)

  

流通市值:93.55亿  总市值:93.55亿
流通股本:4.43亿   总股本:4.43亿

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金868,630,873.99563,582,862.26268,618,755.61837,530,470.82
  收到其他与经营活动有关的现金3,478,923.742,011,791.661,434,238.1840,669,807.54
  经营活动现金流入小计872,109,797.73565,594,653.92270,052,993.79878,200,278.36
  购买商品、接受劳务支付的现金65,119,192.2335,237,666.3315,453,080.3467,762,633.26
  支付给职工以及为职工支付的现金246,548,063.62172,097,134.13102,931,064.51315,576,668.48
  支付的各项税费55,818,626.1139,094,456.9715,525,962.0347,429,193.89
  支付其他与经营活动有关的现金381,766,159.94229,800,322.95111,798,928.8350,466,424.44
  经营活动现金流出小计749,252,041.9476,229,580.38245,709,035.68781,234,920.07
  经营活动产生的现金流量净额122,857,755.8389,365,073.5424,343,958.1196,965,358.29
二、投资活动产生的现金流量:
  收回投资收到的现金2,469,170,348.481,205,610,108.26305,681,247.631,648,646,830.26
  取得投资收益收到的现金17,383,757.837,824,040.394,463,131.5118,839,001.2
  处置固定资产、无形资产和其他长期资产收回的现金净额35,266.0333,633.4516,363.9813,772.78
  投资活动现金流入小计2,486,589,372.341,213,467,782.1310,160,743.121,667,499,604.24
  购建固定资产、无形资产和其他长期资产支付的现金257,087,006.98170,994,824.24100,502,759.4178,602,604.92
  投资支付的现金2,664,663,271.471,554,663,548.47903,854,849.591,706,512,516.66
  投资活动现金流出小计2,921,750,278.451,725,658,372.711,004,357,608.991,885,115,121.58
  投资活动产生的现金流量净额-435,160,906.11-512,190,590.61-694,196,865.87-217,615,517.34
三、筹资活动产生的现金流量:
  吸收投资收到的现金938,339,997.44938,339,997.44938,339,997.44-
  取得借款收到的现金457,160,000330,524,000110,524,000491,902,465
  筹资活动现金流入小计1,395,499,997.441,268,863,997.441,048,863,997.44491,902,465
  偿还债务支付的现金570,284,105.01390,229,368.34123,961,536.67310,941,816.68
  分配股利、利润或偿付利息支付的现金27,454,217.1438,734,750.456,464,846.7131,742,274.07
  支付其他与筹资活动有关的现金110,050,675.756,529,803.665,220,035.0421,618,223.95
  筹资活动现金流出小计707,788,997.85485,493,922.45135,646,418.42364,302,314.7
  筹资活动产生的现金流量净额687,710,999.59783,370,074.99913,217,579.02127,600,150.3
四、汇率变动对现金及现金等价物的影响-1,869,250.84-1,393,957.95-788,180.1-807,474.93
五、现金及现金等价物净增加额373,538,598.47359,150,599.97242,576,491.166,142,516.32
  加:期初现金及现金等价物余额228,682,925.18228,682,925.18228,682,925.18222,540,408.86
  期末现金及现金等价物余额602,221,523.65587,833,525.15471,259,416.34228,682,925.18
补充资料:
  净利润-71,380,590.11-50,959,162.56
  固定资产和投资性房地产折旧-21,204,220.57-36,463,907.12
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-21,204,220.57-36,463,907.12
  无形资产摊销-15,802,119.84-31,287,590.47
  长期待摊费用摊销-1,346,667.11-2,840,932.43
  处置固定资产、无形资产和其他长期资产的损失--6,650--
  固定资产报废损失-80,769.77-69,711.8
  公允价值变动损失--1,431,165.15--238,945.2
  财务费用-17,921,658.03-22,789,141.43
  投资损失-14,005,368.5-25,076,401.36
  递延所得税-1,307,845.59--1,454,462.3
  其中:递延所得税资产减少-266,095.04--1,368,285.04
    递延所得税负债增加-1,041,750.55--86,177.26
  存货的减少--8,795,352.43--16,838,616.46
  经营性应收项目的减少--15,398,421.23--160,139,574.06
  经营性应付项目的增加--27,370,829.1-102,645,815.36
  其他--2,548,208.44--1,969,373.64
  现金的期末余额-587,833,525.15-228,682,925.18
  减:现金的期初余额-228,682,925.18-222,540,408.86
  现金及现金等价物的净增加额-359,150,599.97-6,142,516.32
公告日期2026-10-282026-08-202026-04-302026-03-31
审计意见(境内)标准无保留意见
TOP↑